Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Metabolic diseases, such as obesity, metabolic syndrome (MetS) and type 2 diabetes (T2D),
are now a widespread pandemic in the developed world. These pathologies show sex …

Obesity and type 2 diabetes mellitus (T2DM) are widespread, non-communicable diseases
that are responsible for considerable levels of morbidity and mortality globally, primarily in …

OBJECTIVE To compare the efficacy and safety of once-weekly semaglutide 1.0 mg sc with
exenatide extended release (ER) 2.0 mg sc in subjects with type 2 diabetes. RESEARCH …

In order to ensure normal body function, the human body is dependent on a tight control of
its blood glucose levels. This is accomplished by a highly sophisticated network of various …

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has
been widely appreciated that obesity is a major risk factor for CVD, treatments that produce …

Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …

The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …

During the past 30 yr, investigating the physiology of eating behaviors has generated a truly
vast literature. This is fueled in part by a dramatic increase in obesity and its comorbidities …

The gastrointestinal tract hosts the largest ecosystem of microorganisms in the body. The
metabolism of ingested nutrients by gut bacteria produces novel chemical mediators that …